Your session is about to expire
← Back to Search
Antiviral Agent
Group A for Chronic Obstructive Pulmonary Disease
Phase 1
Waitlist Available
Led By David Wyatt, MD
Research Sponsored by Altesa Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 3 weeks
Awards & highlights
Study Summary
This trial is testing the safety and effectiveness of vapendavir, an antiviral agent, in healthy and COPD patients. Up to 24 adults will be included; follow-up will last 14-30 days.
Eligible Conditions
- Chronic Obstructive Pulmonary Disease
- Respiratory Diseases
- Lower Respiratory Infection
- Lung Disease
- Healthy Subjects
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, up to 3 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 3 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pharmacokinetic Analyses
Trial Design
2Treatment groups
Experimental Treatment
Group I: Group BExperimental Treatment1 Intervention
Participants with COPD
Group II: Group AExperimental Treatment1 Intervention
Healthy Participants (HP)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vapendavir
2015
Completed Phase 2
~460
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Altesa Biosciences, Inc.Lead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
David Wyatt, MDPrincipal InvestigatorVP Medical Affairs
3 Previous Clinical Trials
166 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger